Archived ASX Releases

2011 Releases

CSL announces A$900m share buy-back
CSL Limited today announced a new on-market buy-back of up to A$900 million of CSL shares. More.

Full Year Results Announcement for 2010/11
CSL Limited today reported a net profit after tax of $941 million for the twelve months ended 30 June 2011, down $112 million or 11% when compared to the prior comparable period. More.

CSL Announces Changes to the Board
CSL Limited (ASX:CSL) today announced that Chairman, Miss Elizabeth Alexander, AM, and Director, Mr David Simpson, have indicated their intention to retire from the CSL Board of Directors at the conclusion of the Company’s Annual General Meeting on 19 October 2011. More.

CSL Biotherapies Statement on FDA Warning Letter for GMP issues at Australian Influenza Vaccine Facility
Today the US Food and Drug Administration (FDA) published a Warning Letter issued by its Office of Compliance and Biologics Quality to CSL Biotherapies, a division of CSL Limited. The FDA regulates the manufacture, marketing and distribution of CSL Biotherapies’ influenza vaccine, Afluria®, in the US market. More.

Overview of CSL Behring Innovations in Recombinant Technologies Presented at International Conference
CSL Limited (ASX:CSL) subsidiary, CSL Behring, today issued a press release regarding advances that it is making in developing innovative new technologies to meet the unmet therapeutic needs of patients with haemophilia A and B. More.

Changes to CSL Senior Executive Group
CSL Limited (ASX:CSL) Australia’s leading biopharmaceutical company, today announced a change to its senior executive group. More.

Half-year results announcement for 2010/11
CSL Limited today announced its first half result for period ended 31 December 2010. More.

CSL Appoints New Director
CSL Limited (ASX:CSL) today announced that Ms Christine O’Reilly has been appointed a Director of the Company effective from 16 February 2011. More.

© 2017 CSL Limited